Esperion Therapeutics ESPR Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's other accrued liabilities?
- Esperion Therapeutics (ESPR) reported other accrued liabilities of $1M in Q1 2026.
- How has Esperion Therapeutics's other accrued liabilities changed year-over-year?
- Esperion Therapeutics's other accrued liabilities decreased by 21.4% year-over-year, from $1.27M to $1M.
- What is the long-term trend for Esperion Therapeutics's other accrued liabilities?
- Over 5 years (2020 to 2025), Esperion Therapeutics's other accrued liabilities has grown at a -47.1% compound annual growth rate (CAGR), from $24.79M to $1.03M.